Liver Cancer pp 212-229 | Cite as

Biology of Colorectal Cancer Liver Metastasis

  • Chul Ho Cho
  • Robert Radinsky
Part of the M.D. Anderson Solid Tumor Oncology Series book series (MDA)


Metastasis—the spread of malignant tumor cells from a primary neoplasm to distant parts of the body where they multiply to form new growths—is a major cause of death from cancer. The treatment of metastatic cancer poses a major problem to clinical oncologists because the presence of multiple metastases makes complete eradication by surgery, irradiation, or drugs nearly impossible. For most tumors, including colorectal carcinoma, the presence of liver metastasis renders the patient essentially incurable. A better understanding of the biology of liver metastases and the molecular events leading to the metastatic phenotype is essential if new and innovative therapeutic approaches are to be developed to treat this disease.


Epidermal Growth Factor Receptor Liver Metastasis Nude Mouse Hepatocyte Growth Factor Liver Regeneration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pickren JW, Tsukada Y, Lane WW. Liver metastasis: analysis of autopsy data. In: Weiss L, Gilbert H A, (eds). Liver Metastasis, Boston, GK Hall, 1982, pp. 2–18.Google Scholar
  2. 2.
    Kitadai Y, Radinsky R, Bucana CD, et al. Regulation of carcinoembryonic antigen expression in human colon carcinoma cells by the organ environment. Am J Pathol 149:1157, 1996PubMedGoogle Scholar
  3. 3.
    Gohji K, Fidler IJ, Tsan R, et al. Human recombinant interferons-beta and -gamma decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int J Cancer 58:380, 1994PubMedCrossRefGoogle Scholar
  4. 4.
    Nakajima M, Morikawa K, Fabra A, et al. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 82:1890, 1990PubMedCrossRefGoogle Scholar
  5. 5.
    Dong Z, Radinsky R, Fan D, et al. Organ specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 86:913, 1994PubMedCrossRefGoogle Scholar
  6. 6.
    Fidler IJ, Wilmanns C, Staroselsky A, et al. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13:209, 1994PubMedCrossRefGoogle Scholar
  7. 7.
    Radinsky R. Paracrine growth regulation of human colon carcinoma organ-specific metastases. Cancer Metastasis Rev 12:345, 1993PubMedCrossRefGoogle Scholar
  8. 8.
    Radinsky R, Risin S, Fan D, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1:19, 1995PubMedGoogle Scholar
  9. 9.
    Radinsky R. Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 14:323, 1995PubMedCrossRefGoogle Scholar
  10. 10.
    Fidler IJ. Special lecture: critical factors in the biology of human cancer metastasis: twenty-eighth G. H. A. Clowes Memorial Award Lecture. Cancer Res 50:6130, 1990PubMedGoogle Scholar
  11. 11.
    Fidler IJ, Radinsky R. Genetic control of cancer metastasis [editorial]. J Natl Cancer Inst 82:166, 1990PubMedCrossRefGoogle Scholar
  12. 12.
    Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 55:87, 1990PubMedCrossRefGoogle Scholar
  13. 13.
    Boring CC, Squires TS, Tong T. Cancer statistics 1993. CA Cancer J Clin 41:7, 1993CrossRefGoogle Scholar
  14. 14.
    Russell AH, Tong D, Dawson LE, et al. Adenocarcinoma of the proximal colon: sites of initial dissemination and patterns of recurrence following surgery alone. Cancer 53:360, 1984PubMedCrossRefGoogle Scholar
  15. 15.
    Benotti P, Steele G. Patterns of recurrent colorectal cancer and recovery surgery. Cancer 70:1409, 1992PubMedCrossRefGoogle Scholar
  16. 16.
    Buyse M, Zelenuick-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer: why we still don’t know. JAMA 259:3571, 1988PubMedCrossRefGoogle Scholar
  17. 17.
    Pestana C, Reitemeier RJ, Moertel CG, et al. The natural history of carcinoma of the colon and rectum. Am J Surg 108:826, 1964PubMedCrossRefGoogle Scholar
  18. 18.
    Giavazzi R, Campbell DE, Jessup JM, et al. Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites of nude mice. Cancer Res 46:1928, 1986PubMedGoogle Scholar
  19. 19.
    Morikawa K, Walker SM, Jessup JM, et al. In vivo selection of highly metastatic cells from surgical specimens of different colon carcinomas implanted into nude mice. Cancer Res 48:1943, 1988PubMedGoogle Scholar
  20. 20.
    Morikawa K, Walker SM, Nakajima M, et al. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48:6863, 1988PubMedGoogle Scholar
  21. 21.
    Giavazzi R, Jessup JM, Campbell DE, et al. Experimental nude mouse model of human colorectal cancer liver metastasis. J Natl Cancer Inst 77:1303, 1986PubMedGoogle Scholar
  22. 22.
    Singh RK, Tsan R, Radinsky R. Influence of the host microenvironment on the clonal selection of human colon carcinoma cells during primary tumor growth and metastasis. Clin Exp Metastasis, 15:140, 1997PubMedCrossRefGoogle Scholar
  23. 23.
    Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1:571, 1889CrossRefGoogle Scholar
  24. 24.
    August DA, Ottow RT, Sugarbaker EV. Clinical perspectives of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303, 1984PubMedCrossRefGoogle Scholar
  25. 25.
    Deuel TF. Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol 3:443, 1987PubMedCrossRefGoogle Scholar
  26. 26.
    Zarrilli R, Bruni CB, Riccio A. Multiple levels of control of insulin-like growth factor gene expression. Mol Cell Endocrinol 101:R1, 1994PubMedCrossRefGoogle Scholar
  27. 27.
    Stiles CD, Capone GT, Scher CD, et al. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 76:1279, 1979PubMedCrossRefGoogle Scholar
  28. 28.
    Long L, Nip J, Brodt P. Paracrine growth stimulation by hepatocyte-derived insulin-like growth factor-1: a regulatory mechanism for carcinoma cells metastatic to the liver. Cancer Res 54:3732, 1994PubMedGoogle Scholar
  29. 29.
    Schwarz LC, Gingras MC, Goldberg G, et al. Loss of growth factor dependence and conversion of transforming growth factor-β1 inhibition to stimulation in metastatic Hras-transformed murine fibroblasts. Cancer Res 48:6999, 1988PubMedGoogle Scholar
  30. 30.
    Fan D, Chakrabarty S, Seid C, et al. Clonal stimulation or inhibition of human colon carcinomas and human renal carcinoma mediated by transforming growth factor-β1. Cancer Commun 1:117, 1989PubMedGoogle Scholar
  31. 31.
    Maiden L, Novak U, Burgess A. Expression of transforming growth factor alpha messenger RNA in normal and neoplastic gastrointestinal tract. Int J Cancer 43:380, 1989CrossRefGoogle Scholar
  32. 32.
    Markowitz SD, Molkentin K, Gerbic C, et al. Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor receptor in normal an adenomatous human colon epithelium. J Clin Invest 86:356, 1990.PubMedCrossRefGoogle Scholar
  33. 33.
    Mead JE, Fausto N. Transforming growth factor a may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 86:1558, 1989PubMedCrossRefGoogle Scholar
  34. 34.
    Michalopoulos GK, DeFrances MC. Liver regeneration. Science 276:60, 1997PubMedCrossRefGoogle Scholar
  35. 35.
    Gutman M, Singh RK, Price JE, et al. Accelerated growth of human colon cancer cells in nude mice undergoing liver regeneration. Invasion Metastasis 14:362, 1994–1995Google Scholar
  36. 36.
    Barbera-Guillem E, Smith I, Weiss L. Cancer-cell traffic in the liver. I. Growth kinetics of cancer cells after portal-vein delivery. Int J Cancer 52:974, 1992PubMedCrossRefGoogle Scholar
  37. 37.
    Jessup JM, Thomas P. Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma. Cancer Metastasis Rev 8:263, 1989PubMedCrossRefGoogle Scholar
  38. 38.
    Hashino J, Fukuda Y, Oikawa S, Nakazato H, Nakanishi T. Metastatic potential of human colorectal carcinoma SW1222 cells transfected with cDNA encoding carcinoembryonic antigen. Clin Exp Metastasis 12:324, 1994PubMedCrossRefGoogle Scholar
  39. 39.
    Gold P, Freedman SO. Demonstration of tumor-specific antigen in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 121:439, 1965PubMedCrossRefGoogle Scholar
  40. 40.
    Steele G Jr, Zamcheck N. The use of carcinoembryonic antigen in the clinical management of patients with colorectal cancer. Cancer Detect Prev 8:421, 1985PubMedGoogle Scholar
  41. 41.
    Hauck W, Stanners CP. Transcriptional regulation of the carcinoembryonic antigen gene. J Biol Chem 270:3602, 1995PubMedCrossRefGoogle Scholar
  42. 42.
    Toribara NW, Sack TL, Gum JR, et al. Heterogeneity in the induction and expression of carcinoembryonic antigen-related antigens in human colon cancer cell lines. Cancer Res 49:3321, 1989PubMedGoogle Scholar
  43. 43.
    Xie B, Bucana CD, Fidler IJ. Density-dependent induction of 92-kd type IV collagenase activity in cultures of A431 human epidermoid carcinoma cells. Am J Pathol 144:1058, 1994PubMedGoogle Scholar
  44. 44.
    Pinto M, Robine-Leon S, Appay M-D, et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323, 1983Google Scholar
  45. 45.
    Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9:289, 1990PubMedCrossRefGoogle Scholar
  46. 46.
    Testa JE, Quigley JP. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev 9:353, 1990PubMedCrossRefGoogle Scholar
  47. 47.
    Levy A, Cioce V, Sobel ME, et al. Increased expression of the 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res 51:439, 1991PubMedGoogle Scholar
  48. 48.
    Fabra A, Nakajima M, Bucana CD, Fidler IJ. Modulation of the invasive phenotype of human colon carcinoma cells by fibroblasts from orthotopic or ectopic organs of nude mice. Differentiation 52:101, 1992PubMedCrossRefGoogle Scholar
  49. 49.
    Chung LWK. Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Rev 10:263, 1991PubMedCrossRefGoogle Scholar
  50. 50.
    Chin K-V, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 60:157, 1993PubMedCrossRefGoogle Scholar
  51. 51.
    Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 81:116, 1989PubMedCrossRefGoogle Scholar
  52. 52.
    Weinstein RS, Shriram JM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720, 1991PubMedGoogle Scholar
  53. 53.
    Raymond M, Rose E, Housman DE, Gros P. Physical mapping, amplification, and overexpression of the mouse mdr gene family in multidrug-resistant cells. Mol Cell Biol 10:1642, 1990PubMedGoogle Scholar
  54. 54.
    Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10:1652, 1990PubMedGoogle Scholar
  55. 55.
    Croop JM, Raymond M, Haber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 9:1346, 1989PubMedGoogle Scholar
  56. 56.
    Slack NH, Bross JDJ. The influence of site of metastasis on tumor growth and response to chemotherapy. Br J Cancer 32:78, 1975PubMedCrossRefGoogle Scholar
  57. 57.
    Wilmanns C, Fan D, O’Brian CA, et al. Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52:98, 1992PubMedCrossRefGoogle Scholar
  58. 58.
    Staroselsky A, Fan D, O’Brian CA, et al. Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin. Cancer Res 40:7775, 1990Google Scholar
  59. 59.
    Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem 56:37, 1994PubMedCrossRefGoogle Scholar
  60. 60.
    Van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10:251, 1994PubMedCrossRefGoogle Scholar
  61. 61.
    Harris AL, Neal DE. Epidermal growth factor and its receptor in human cancer. In: Sluyser M (ed) Growth Factors and Oncogenes in Breast Cancer. 1987, pp. 60–90Google Scholar
  62. 62.
    Radinsky R, Bucana CD, Ellis LE, et al. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res 53:937, 1993PubMedGoogle Scholar
  63. 63.
    Mendelsohn J. The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol 1:339, 1990PubMedGoogle Scholar
  64. 64.
    Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327, 1993PubMedCrossRefGoogle Scholar
  65. 65.
    Lofts FJ, Hurst HC, Sterberg MJE, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene 8:2813, 1993PubMedGoogle Scholar
  66. 66.
    Dinney CPN, Parker C, Dong Z, et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin Cancer Res 3:161, 1997PubMedGoogle Scholar
  67. 67.
    Selva E, Raden DL, Davis RJ. Mitogen-activated prsotein kinase stimulationby a tyrosine kinase-negative epidermal growth factor receptor. J Biol Chem 268:2250, 1993PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Chul Ho Cho
  • Robert Radinsky

There are no affiliations available

Personalised recommendations